Sleep apnoea in end-stage renal disease: A short review of mechanisms and potential benefit from its treatment

Nephrology Dialysis Transplantation

Volumn 22, Issue 1, 2007, Pages 28-31

  Chakravorty, Indranil ^a   Shastry, Manu ^a   Farrington, Ken ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Chronic heart failure; Continuous positive airway pressure; End stage renal disease; Sleep apnoea

Indexed keywords

CARBON DIOXIDE; OXYGEN;

ADENOIDECTOMY; AIRWAY OBSTRUCTION; ARTERIAL OXYGEN SATURATION; BLOOD PRESSURE REGULATION; CARBON DIOXIDE TENSION; CARDIOVASCULAR RISK; DAYTIME SOMNOLENCE; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; ENURESIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE; NOCTURIA; OXIMETRY; PALATOPLASTY; PERITONEAL DIALYSIS; POLYSOMNOGRAPHY; POLYURIA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SLEEP APNEA SYNDROME; SNORING; SODIUM EXCRETION; TONSILLECTOMY; UVULOPALATOPHARYNGOPLASTY; WEIGHT REDUCTION;

ATRIAL NATRIURETIC FACTOR; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NATRIURETIC PEPTIDE, BRAIN; OXIMETRY; POLYSOMNOGRAPHY; POSITIVE-PRESSURE RESPIRATION; SLEEP APNEA, OBSTRUCTIVE; SLEEP STAGES; TREATMENT OUTCOME;

EID: 33846012202     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl582     Document Type: Review

References (20)

1. Williams GW, Weller JM, Ferguson CW, Forsythe SB, Wu SC. Survival of endstage renal disease patients: Age-adjusted differences in treatment outcomes. Kidney Int 1983; 24: 691-693
2. Powell C. Sleep apnea in end stage renal disease. Anna Journal 1997; 24: 645-654
3. Zoccali C. Sleep apnoea and nocturnal hypoxaemia in dialysis patients: mere risk-indicators or causal factors for cardiovascular disease? Nephrol Dial Transplant 2000; 15: 1919-1921
4. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8: 355-358
5. Chakravorty I, Cayton RM, Szczepura A. Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. Eur Respir J 2002; 20: 1233-1238
6. Wright J, White J. Continuous positive airways pressure for obstructive sleep apnoea. Cochrane Database Syst Rev 2000; CD001106
7. Pressman MR, Benz RL, Schleifer CR, Peterson DD. Sleep disordered breathing in ESRD: Acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 1993; 43: 1134-1139
8. Stradling JR, Davies RJ. Sleep. 1: Obstructive sleep apnoea/hypopnoea syndrome: Definitions, epidemiology, and natural history. Thorax 2004; 59: 73-78
9. De Backer WA. Central sleep apnoea, pathogenesis and treatment: An overview and perspective. [Review] [119 refs]. Eur Respir J 1995; 8: 1372-1383
10. Fletcher EC. Obstructive sleep apnoea and cardiovascular morbidity. Monaldi Archives for Chest Disease 1996; 51: 77-80
11. Elwood P, Hack M, Pickering J, Hughes J, Gallacher J. Sleep disturbance, stroke, and heart disease events: Evidence from the Caerphilly cohort. J Epidemiol Community Health 2006; 60: 69-73
12. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax 2004; 59: 618-622
13. Shneerson J, Wright J. Lifestyle modification for obstructive sleep apnoea (Cochrane Review). Cochrane Database Syst Rev 2001; 1: CD002875
14. Simonds AK. Managing obstructive sleep apnoea. Practitioner 2001; 245: 117-120
15. Hoekema A, Stegenga B, De Bont LG. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: A systematic review. Crit Rev Oral Biol Med 2004; 15: 137-155
16. Krieger J, Schmidt M, Sforza E et al. Urinary excretion of guanosine 3′:5′-cyclic monophosphate during sleep in obstructive sleep apnoea patients with and without nasal continuous positive airway pressure treatment. Clin Sci 1989; 76: 31-37
17. Saarelainen S, Hasan J, Siitonen S, Seppala E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res 1996; 5: 181-185
18. Kinebuchi SI, Kazama JJ, Satoh M et al. The short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnea syndrome. Clin Sci 2004; 107:317-22
19. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA. Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. Nephrol Dial Transplant 2001; 16: 70-77
20. Kita H, Ohi M, Chin K et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 1998; 7: 199-207